tiprankstipranks
Eagle Pharmaceuticals Risks Nasdaq Delisting Over Filing Delays
Company Announcements

Eagle Pharmaceuticals Risks Nasdaq Delisting Over Filing Delays

Don't Miss Our Christmas Offers:

Eagle Pharmaceuticals Inc (EGRX) has issued an announcement.

Eagle Pharmaceuticals, Inc. is currently facing non-compliance issues with Nasdaq’s listing requirements due to delays in filing its annual and quarterly financial reports. The company has received a notice regarding its failure to file the necessary reports and is at risk of being delisted if it cannot regain compliance. Although Eagle Pharmaceuticals has been granted an extension until May 13, 2024, to address these issues, it has indicated doubt in meeting this deadline and may face delisting proceedings, which could lead to a hearing to maintain its Nasdaq listing.

For detailed information about EGRX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskEagle Pharmaceuticals Appoints New CFO Amid Leadership Change
TheFlyEagle Pharmaceuticals appoints Christopher Krawtschuk as CFO
TipRanks Auto-Generated NewsdeskEagle Pharmaceuticals Implements Stockholder Rights Plan
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App